J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
Judith G. Villablanca,Mark Krailo,Matthew M. Ames,Joel M. Reid,Gregory H. Reaman,C. Patrick Reynolds +5 more
TL;DR: The pediatric MTD of oral capsular fenretinide was 2,475 mg/m2 per day, which achieved levels active against neuroblastoma in vitro with minimal toxicity, and response data support a phase II trial in Neuroblastoma.
Journal ArticleDOI
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
Brenda J. Weigel,Suman Malempati,Joel M. Reid,Stephan D. Voss,Steven Y. Cho,Helen X. Chen,Mark Krailo,Doojduen Villaluna,Peter C. Adamson,Susan M. Blaney +9 more
TL;DR: This phase 2 study was designed to assess the efficacy of single agent cixutumumab (IMC‐A12) and gain further information about associated toxicities and pharmacodynamics in children, adolescents, and young adults with recurrent or refractory solid tumors.
Journal ArticleDOI
Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide
Rae Myers,Suzanne Greiner,Mary Harvey,Guy E. Griesmann,Mary J. Kuffel,Sarah A. Buhrow,Joel M. Reid,Mark J. Federspiel,Matthew M. Ames,David Dingli,Karen Schweikart,Welch A,Angela Dispenzieri,Kah-Whye Peng,Stephen J. Russell +14 more
TL;DR: The safe starting dose of MV‐NIS for the clinical protocol was set at 1−2 × 104 TCID50/kg (106 TCID50 per patient), more so after pretreatment with cyclophosphamide.
Journal ArticleDOI
Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid Tumors
Alex A. Adjei,Charles Erlichman,Jeff A. Sloan,Joel M. Reid,Henry C. Pitot,Richard M. Goldberg,Prema P. Peethambaram,Pamela J. Atherton,Lorelei J. Hanson,Steven R. Alberts,James R. Jett +10 more
TL;DR: The sequence of gemcitabine administered on days 1 and 8 with MTA administered on day 8 is better tolerated and is recommended for further study at doses of gem citabine/MTA 1,250/500 mg/m(2).
Journal Article
Metabolic Activation of Dacarbazine by Human Cytochromes P450: The Role of CYP1A1, CYP1A2, and CYP2E1
TL;DR: CYP1A2 is the predominant P450 that catalyzes DTIC hepatic metabolism; CYP2E1 contributes to hepatic DTIC metabolism at higher substrate concentrations; and CYP1A1 catalyzes extrahepatic metabolism of DTIC.